Nature Clinical Practice Endocrinology & Metabolism
Drug Insight: Insulin-Sensitizing Drugs in the Treatment of Polycystic Ovary Syndrome – A Reappraisal CME

Disclosures

Release Date: March 25, 2008; Valid for credit through March 25, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

  1. Drug Insight: Insulin-Sensitizing Drugs in the Treatment of Polycystic Ovary Syndrome – A Reappraisal
    Andrea Dunaif, MD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Specify criteria used to diagnose polycystic ovary syndrome (PCOS)
  2. Describe the metabolic effects of insulin-sensitizing drugs among women with PCOS
  3. Describe the effects of insulin-sensitizing drugs on fertility and pregnancy among women with PCOS
  4. Identify adverse effects of insulin-sensitizing drugs
Authors and Disclosures

Andrea Dunaif, MD
Disclosure: Andrea Dunaif, MD, has disclosed no relevant financial relationships.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.


Rachel Ashton
Disclosure: Rachel Ashton has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.